Actos Lawsuit News: Bernstein Liebhard LLP Notes New Case Management Order in Federal Actos Bladder Cancer Litigation

Share Article

The Firm is currently evaluating Actos lawsuits on behalf of Individuals who developed bladder cancer, allegedly due to long-term use of Actos.

Free Case Review
We continue to receive Actos lawsuit inquiries from individuals who allege long-term use of this drug resulted in their bladder cancer diagnosis. We are pleased to see the federal litigation moving forward.

Actos lawsuit claims pending in a federal multidistrict litigation underway in U.S. District Court, Western District of Louisiana, continue to move forward, Bernstein Liebhard LLP reports. According to a Case Management Order issued on May 21st, the Court has established procedures that govern the filing of contested motions in the Actos bladder cancer litigation, as well as deadlines for filing those motions. (In re: Actos Product Liability Litigation, MDL No. 2299)

“We continue to receive Actos lawsuit inquiries from individuals who allege long-term use of this drug resulted in their bladder cancer diagnosis. We are pleased to see the federal litigation moving forward,” says Bernstein Liebhard LLP, a nationwide law firm representing the victims of defective drugs and medical devices. The Firm is currently offering free legal evaluations to alleged victims of Actos bladder cancer.

Actos Bladder Cancer Allegations
The federal Actos bladder cancer litigation was established in December 2011, after the U.S. Food & Drug Administration (FDA) issued a Public Health Alert in June of that year warning that long-term use of Actos had been linked to an increased risk of bladder cancer.* According to a May 1st Bloomberg.com report, more than 1,200 Actos bladder cancer claims are pending in the Louisiana litigation, while additional Actos lawsuits have been filed in state litigations in California and Illinois. Actos lawsuit plaintiffs allege Takeda Pharmaceuticals failed to provide adequate warnings to doctors and patients regarding the drug’s association with an increased risk of bladder cancer.**

In April, a California Superior Court jury hearing the nation’s first Actos bladder cancer trial returned a verdict in favor of the Plaintiff, awarding $6.5 million to a man who was diagnosed with the disease after taking Actos for four years. However, the judge overseeing the case granted Takeda Pharmaceuticals’ request to set aside the verdict. (Cooper v. Takeda Pharmaceuticals America Inc., CGC-12-518535, California Superior Court) Court documents indicate that the first trials in the federal Actos litigation will begin in January 2014.

Alleged victims of Actos bladder cancer may be entitled to compensation for medical expenses, lost wages, pain and suffering, and more. Learn more about filing an Actos lawsuit by visiting Bernstein Liebhard LLP’s website. For additional information, please call 800-511-5092 today.

*FDA, June 15, 2011; fda.gov/drugs/drugsafety/ucm259150.htm
**bloomberg.com/news/2013-05-01/takeda-gets-6-5-million-diabetes-drug-verdict-thrown-out.html

About Bernstein Liebhard LLP
Bernstein Liebhard LLP is a New York-based law firm exclusively representing injured persons in complex individual and class action lawsuits nationwide since 1993, including those who have been harmed by dangerous drugs, defective medical devices and consumer products. The firm has been named by The National Law Journal to the “Plaintiffs’ Hot List,” recognizing the top plaintiffs’ firms in the country, for the past 10 consecutive years.

Bernstein Liebhard LLP
10 East 40th Street
New York, New York 10016
800-511-5092

ATTORNEY ADVERTISING. © 2013 Bernstein Liebhard LLP. The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, (212) 779-1414. Prior results do not guarantee or predict a similar outcome with respect to any future matter.
###

Contact Information:
Felecia L. Stern, Esq.
Bernstein Liebhard LLP
info(at)consumerinjurylawyers(dot)com
http://www.consumerinjurylawyers.com

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Felecia L. Stern
Follow us on
Visit website